530313
Kimia Bioscien. financials
- Market cap
- ₹140 Cr
- Sector
- Healthcare
What Kimia Bioscien. does
Kimia Biosciences is engaged in the manufacture, marketing and trading of Active Pharmaceutical Ingredients (APIs)/bulk drugs and their intermediates, addressing a range of high-potential therapeutic segments. Product is manufactured on a job-work basis at third-party facilities located in Derabassi (Punjab) and other locations in India, rather than at company-owned production lines. The company runs a DSIR-recognised in-house R&D centre focused on process development, cost improvement of existing APIs and indigenous (in-house) development of key starting materials/raw materials to reduce import dependence.
Segments
- Active Pharmaceutical Ingredients (APIs) / bulk drugs
- API / bulk drug portfolio
- 17+ APIs across anticoagulant, anti-diabetic, antihypertensive, antibiotic, antihistamine & other therapeutic segments
- Manufacturing model
- Job-work manufacturing at third-party facilities in Derabassi (Punjab) and other locations in India
- R&D Centre
- DSIR-recognised in-house R&D facility at Village Bhondsi, Sohna, Gurugram (Regn. No. TU/IV-RD/4410/2021)
- Key starting materials (KSMs) developed in-house
- 9 (incl. Bilastine KSM, Fima KSM, Glycidyl phthalimide, TPI-BOC, INB-Acetoacetate)
- Plant certification
- GMP-certified by State FDA, Haryana
- Industry association memberships
- 5 (PHARMCIL, HEMS, CII, DCC, FOPE)
Quarterly results
Q1 FY27: revenue down 12.1%, net profit down 40.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 28 | 30 | 38 | 24 | 34 +21% | 30 +0% | 27 −29% | 21 −12% |
| EBITDA | 3 | 5 | 8 | 3 | 3 −25% | 7 +31% | 3 −67% | 2 −7% |
| Net profit | 2 | 5 | 2 | 1 | 1 −37% | 5 +19% | 0 −81% | 0 −40% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −24.2% 1Y
1Y: ₹35.92 on 10 Sept 2025 → ₹27.24. High ₹41.76 (13 Feb 2026), low ₹23.55 (30 Mar 2026).
Financials, as filed
Revenue fell 3.7% a year over 3 years, FY23 to FY26. Operating margin widened to 12.4%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹129 Cr | ₹105 Cr | ₹119 Cr | ₹115 Cr |
| Operating profit | ₹-5 Cr | ₹-0 Cr | ₹20 Cr | ₹14 Cr |
| Operating margin | -3.9% | -0.5% | 17.0% | 12.4% |
| Interest | ₹4 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr |
| Depreciation | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr |
| Net profit | ₹-9 Cr | ₹-5 Cr | ₹10 Cr | ₹7 Cr |
| Net margin | -7.3% | -5.1% | 8.1% | 6.5% |
| Cash from operations | ₹-7 Cr | ₹15 Cr | ₹21 Cr | ₹11 Cr |
| Free cash flow | ₹-10 Cr | ₹13 Cr | ₹17 Cr | ₹3 Cr |
| ROCE | -12.0% | -4.0% | 42.0% | 25.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr |
| Reserves | ₹14 Cr | ₹10 Cr | ₹1 Cr | ₹-1 Cr | ₹7 Cr | ₹13 Cr |
| Borrowings | ₹45 Cr | ₹41 Cr | ₹53 Cr | ₹39 Cr | ₹36 Cr | ₹35 Cr |
| Other liabilities | ₹43 Cr | ₹54 Cr | ₹63 Cr | ₹57 Cr | ₹54 Cr | ₹51 Cr |
| Total liabilities | ₹107 Cr | ₹109 Cr | ₹121 Cr | ₹99 Cr | ₹101 Cr | ₹103 Cr |
| Fixed assets | ₹28 Cr | ₹35 Cr | ₹34 Cr | ₹31 Cr | ₹34 Cr | ₹37 Cr |
| Capital work in progress | ₹6 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹72 Cr | ₹74 Cr | ₹87 Cr | ₹68 Cr | ₹68 Cr | ₹66 Cr |
| Total assets | ₹107 Cr | ₹109 Cr | ₹121 Cr | ₹99 Cr | ₹101 Cr | ₹103 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025. The shareholder count grew 5% to 12,775.
- Promoters
- 74.9%
- DIIs
- 0.4%
- Public
- 24.7%
Since Jun 2025
- Promoters 0.00 pp
- DIIs 0.00 pp
- Public 0.00 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 74.9%, DIIs 0.4%, Public 24.7%.Dec '23: Promoters 74.9%, DIIs 0.4%, Public 24.7%.Mar '24: Promoters 74.9%, DIIs 0.4%, Public 24.7%.Jun '24: Promoters 74.9%, DIIs 0.4%, Public 24.7%.Sep '24: Promoters 74.9%, DIIs 0.4%, Public 24.7%.Dec '24: Promoters 74.9%, DIIs 0.4%, Public 24.7%.Mar '25: Promoters 74.9%, DIIs 0.4%, Public 24.7%.Jun '25: Promoters 74.9%, DIIs 0.4%, Public 24.7%.Sep '25: Promoters 74.9%, DIIs 0.4%, Public 24.7%.Dec '25: Promoters 74.9%, DIIs 0.4%, Public 24.7%.Mar '26: Promoters 74.9%, DIIs 0.4%, Public 24.7%.Jun '26: Promoters 74.9%, DIIs 0.4%, Public 24.7%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Kimia Bioscien. above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Sameer Goel | 74.94% | unchanged |
| Anish Kumar Aggarwal | 4.33% | unchanged |
| Manish Gupta | 4.25% | unchanged |
| Roma Mittal | 4.11% | unchanged |
| Rahul Agrawal | 3.33% | unchanged |
| Santosh Goel | 0.00% | unchanged |
| Vandana Goel | 0.00% | unchanged |
| Vipul Goel | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Kimia Bioscien.
Guides on how to read this kind of business and the numbers that matter.